INAB earnings date and last-quarter result: last quarter miss, P/E -0.33. Updated 2026-07-23.
IN8bio (INAB) Research Hub
IN8bio (INAB) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 0.9655 USD (-8.05%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.33, market cap 0.01B. This hub links to the full technical, earnings and options research available for INAB.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 0.9655 USD (-8.05%) |
| 52-week range | 0.9 USD – 1.53 USD |
| Trend regime | Range |
| 14-day RSI | 20.2 (Oversold) |
| Trailing P/E | -0.33 |
| Market cap | 0.01B |
| Dividend yield | 0.00% |
Available research for INAB
Covered Call on INAB: how it works, illustrative setup around the real 0.9655 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on INAB: how it works, illustrative setup around the real 0.9655 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on INAB: how it works, illustrative setup around the real 0.9655 USD price, max profit/loss, breakeven and when to use it. Educational.
INAB technical analysis: range, last 0.9655 USD, RSI 20.2, 52w range 0.9 USD–1.53 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is INAB in?
IN8bio (INAB) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is INAB in an uptrend or downtrend?
As of 2026-10-26, INAB is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is INAB's trailing P/E ratio?
INAB's trailing P/E is -0.33, with a market cap of 0.01B. See the earnings research page for full valuation detail.